Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging Evidence.

J Curr Glaucoma Pract · 2025 · PMC12780357 · PMID 41523168

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

found that, when all studies were included, the pooled HR for glaucoma incidence among GLP-1 RA users did not reach statistical significance, likely due to heterogeneity and the influence of one outlier study.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.